MétaCan
Menu
← Back to cohort

Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2024· article· en· W4399394976 on OpenAlexaff
Karim Fizazi, Whijae Roh, Arun Azad, Xinmeng Jasmine Mu, Nobuaki Matsubara, Steven Yip, Stefanie Zschaebitz, Josep M. Piulats, Glenn Liu, Robert J. Jones, Michelle Saul, Arne Engelsberg, Jijumon Chelliserry, Douglas Laird, Neeraj Agarwal

Bibliographic record

VenueJournal of Clinical Oncology · 2024
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsBaker Hughes (Canada)
FundersPfizer
KeywordsMedicineEnzalutamideNon-negative matrix factorizationHomologous recombinationInternal medicineMatrix decompositionGeneticsCancerGeneBiology

Abstract

fetched live from OpenAlex

5021 Background: TP-2 (NCT03395197) demonstrated significantly improved radiographic progression-free survival (rPFS) in pts with mCRPC who received TALA + ENZA (n=402) vs PBO + ENZA (n=403). We discovered a novel NMF-based HRD score and used it to explore potential associations of HRD with efficacy in TP-2. Methods: The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) dataset was used to train a novel NMF-based HRD predictive score incorporating gene expression (RNA seq) and homologous recombination repair (HRR)12 genomic features (mutations possibly or probably damaging by PolyPhen, deleterious by SIFT, or shallow/deep deletion; HRR12 genes: BRCA1, BRCA2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12). A previously published composite HRD score incorporating genomic loss of heterozygosity, large scale transitions, and telomeric allelic imbalances (Knijnenburg et al. Cell Rep. 2018;23:239-254.e6) was used as the “original” HRD reference score. HRR12 genomic features in TCGA-PRAD were associated with higher original and predicted HRD scores. Two datasets were used to generate the HRD score for TP-2: a FoundationOneLiquid CDx (F1LCDx) dataset (Azad et al. ASCO 2023, #5056) of prospectively collected/retrospectively analyzed plasma samples (n=681) and a tumor transcriptomic dataset generated via HTG’s Oncology Biomarker Panel (with 10 additional genes implicated in PARPi sensitivity; n=304). This NMF-based HRD score was then applied to the evaluable TP-2 safety population (n=285). Predicted HRD scores for TP-2 were categorized as high (≥0.46 [median]) or low (

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.004
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.117
GPT teacher head0.457
Teacher spread0.340 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicPARP inhibition in cancer therapy→French-language works237,207→